BridgeBio Pharma Stock Surges as AstraZeneca's Rival Heart Drug Fails Phase III Trial

BridgeBio Pharma (NASDAQ: BBIO) shares surged in pre-market trading after a pivotal Phase III trial for a competing heart disease drug developed by AstraZeneca and Ionis failed to meet its primary goals. The development significantly reduces the competitive threat in the market for treatments for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Rival Drug Trial Fails

AstraZeneca and Ionis announced that their drug, Wainua, did not meet its primary efficacy endpoint in the CARDIO-TTRansform Phase III trial. The study evaluated Wainua's ability to reduce a composite of cardiovascular mortality and recurrent cardiovascular events compared to a placebo over 140 weeks in patients with ATTR-CM.

The trial's failure is a direct benefit to BridgeBio, whose drug Attruby competes in the same indication. According to the results, Wainua showed no treatment effect in patients who were already using stabilizer-based standard care, a key detail that reinforces the competitive standing of existing treatments like Attruby.

Market Impact

The news prompted an immediate and significant market reaction. Key takeaways include:

Ad

• BridgeBio Pharma's stock jumped 12.4% in pre-open trading.
• AstraZeneca (NASDAQ: AZN) shares fell sharply on the news.
• Alnylam Pharmaceuticals (NASDAQ: ALNY), another competitor in the ATTR-CM space, also saw its shares rally as the competitive field narrowed.

The outcome solidifies the position of BridgeBio's oral TTR stabilizer, Attruby, as a leading treatment. Attruby received FDA approval in November 2024 for adults with ATTR-CM and has demonstrated a strong commercial launch, with U.S. sales reportedly reaching $362.4 million in 2025 and nearly $181 million in the first quarter of 2026.

Context and Outlook

The surge adds to an already strong performance for BridgeBio, which had seen its stock rise for nine consecutive trading sessions prior to the announcement. This latest development further bolsters the company's outlook as it seeks to expand its commercial footprint in the rare-disease market.

BridgeBio has several other products in its late-stage pipeline, including three potential U.S. launches on the horizon for different conditions. The failure of a key competitor's drug provides a clearer path for Attruby's continued growth and strengthens investor confidence in the company's market position.